Same to you Drano....my thoughts/opinions on the new year are that IPIX will be a very different company by the summer. The way I see it is they have completed the mid-stage trials they were intending to in an effort to maximize the value of the company and have had substantial success in many of those trials to date. While they mention moving forward on some of the current indications, it is not as clear cut or vigorous as it was when the current trials were in the planning stages. That to me suggests that they are satisfied with where the indications are in their development and they are ready to partner with those that can take the drugs through the next steps to commercialization. My hunch is that the entire B platform has a BP suitor and that will happen once the B-OM secondary endpoint data becomes available. I could be totally off base though and these are just MHO.